In-vitro Diagnostics Market Size By Type (Product [Reagents & Kits, Instruments], Service [Software, Testing Services]), By Technology (Clinical Chemistry, Immunoassay/Immunochemistry, Molecular Diagnostics, Hematology, Microbiology, Coagulation & Hemostasis, Urinalysis), By Application (Oncology, Infectious Diseases, Diabetes, Cardiology, Nephrology, Autoimmune Diseases, Drug Testing/ Pharmacogenomics) By End-user (Hospitals, Point-Of-Care Testing, Laboratories, Academic Institutes), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, France, UK, Italy, Spain, Russia, China, Japan, India, Australia, Brazil, Mexico, Saudi Arabia, South Africa, UAE), Application Potential, Competitive Market Share & Forecast, 2019 – 2025

Industry Trends

In-vitro diagnostics market size was valued at USD 66.4 billion in 2018 and is expected to witness over 5.5% CAGR from 2019 to 2025.
 

U.S. In-vitro Diagnostics Market, By Type, 2018 & 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Technological advancements in in-vitro diagnostic tools is the primary factor driving business growth. Focus of business players on introduction of innovative and cutting-edge in-vitro diagnostic (IVD) products will foster business growth. For instance, Qiagen, one of the leading providers of point of care molecular diagnostics, offers advanced products that deliver highest accuracy results for specific patient treatments. Several such advances will accelerate in vitro diagnostics business growth.
 

Furthermore, rising investments in the improvement of healthcare sector by government and other organizations will serve to be positive impact rendering factor in the business growth. Numerous initiatives undertaken by government to provide information and education about personalized medication and IVD tools for efficient patient management will spur in-vitro diagnostics business size. However, excessive cost of in-vitro diagnosis services may hinder industry growth during the forecast period.
 

Request 15% Free Customization on this Report
 

In-vitro Diagnostics Market, By Type

Product segment held around 25% revenue share in 2018 and is projected to grow substantially by 2025. Increasing burden of infectious diseases will surge the demand for in-vitro diagnostic reagents and kits. Focus of business players on developing advanced kits for quick and reliable diagnosis should augment segmental growth.
 

Service segment is estimated to show robust CAGR of around 5% over the analysis period. Growing demand for software in diagnostic testing services by clinicians and doctors to diagnose various chronic diseases will boost the business growth.
 

In-vitro Diagnostics Market, By Technology

Clinical chemistry segment was valued over USD 13.5 billion in 2018 and is estimated to show similar growth over the coming years. Various applications of clinical chemistry including detection of hormone fluctuations and blood glucose levels will propel overall segmental growth.
 

Urinalysis segment held considerable revenue share in 2018 and is projected to show more than 5.5% CAGR over forecast period. Segment growth is attributable to increasing prevalence of kidney disorders in developed as well as developing economies.
 

Germany In-vitro Diagnostics Market Size, By Technology, 2018 (USD Million)

Get more details on this report - Request Free Sample PDF
 

In-vitro Diagnostics Market, By Application

Cardiology segment was valued over USD 11 billion in 2018 and will exhibit lucrative growth over the coming years. Rising prevalence of cardiovascular diseases such as coronary artery disease, arrhythmia and stroke globally will drive demand for in-vitro diagnostics tools.
 

Oncology segment held considerable revenue share in 2018 and is projected to witness more than 6% CAGR during analysis period. Availability of advanced home kits such as fecal occult blood test (FOBT) for diagnosis of colon cancer in homecare settings will prove beneficial for segment growth.
 

In-vitro Diagnostics Market, By End-user

Hospitals segment was valued around USD 20 billion in 2018 and will exhibit significant growth during the forthcoming years. Presence of skilled healthcare professionals and technologically progressive medical devices in hospitals will foster business growth over the analysis period.
 

Point of care testing segment held considerable revenue share in 2018 and is estimated to show more than 6.5% CAGR during the forecast period. Point of care diagnostic tests include biosensors, pregnancy kits and glucose meters among others that ensure quick and accurate results. Growing demand for such point of care products and services will thus augment segmental growth.
 

In-vitro Diagnostics Market, By Region

North America in-vitro diagnostics market is projected to show around 5.5% CAGR over the analysis timeline. Growing disease burden in the region and awareness among people regarding availability of advanced products will spur regional business size. Moreover, strong foothold of prominent business players will upsurge North America in vitro diagnostics industry growth.
 

Asia Pacific in-vitro diagnostics business was valued over USD 13 billion in 2018. Regional growth can be attributed to the on-going trends in the IVD market such as PCR and flow cytometry among others. Growing healthcare expenditure and various healthcare reforms in Asia Pacific will further boost regional business growth.
 

Asia Pacific In-vitro Diagnostics Market Size, By Country, 2025 (USD Million)

Get more details on this report - Request Free Sample PDF
 

Competitive Market Share

Some of the notable industry players operating in in-vitro diagnostics market include Johnson & Johnson, Cephied, BioMerieux, Qiagen, Becton Dickinson, Danaher, Abbott, BioRad, Grifols, Luminex, Siemens, Sorin, Thermo Fisher Scientific and Roche Diagnostics. Manufacturers focus on novel product launch, introduction of newer technology within analytical instruments and inorganic strategies to raise their revenue share and sustain market competition.
 

Recent industry developments:

• In July 2018, Thermo Fisher Scientific launched Phadia 200 for diagnosis of allergy & autoimmune conditions. The new product launch enabled the company to gain more revenue share.
   
• In March 2017, Cepheid launched Xpert MTB/RIF Ultra, a new test for diagnosis of TB with an aim to diversify its product portfolio and  capitalize on market opportunities.
   

In-vitro Diagnostics Industry Background

History of in-vitro diagnostics industry can be traced back to early 1980s. Kary Mullis, in 1983, introduced the PCR technique with an aim to improve patient care. Further in the 20^th century, Efforts were taken to supplement the in-vitro diagnostics with technology. Business players such as Thermo Fisher and Roche among others aimed at integrating technological advancements in the diagnostic devices, that eventually had a positive impact on business growth. In-vitro diagnostics industry is consolidated in nature and is completely depended on adoption rates of diagnostic devices and economic potential in laboratories and hospitals. It can prove cost-effective in assisting elderly to stay independently at home for longer time. In-vitro diagnostics industry has witnessed momentous developments over the recent years. Advent in technology will surge the demand for in-vitro diagnostics, thereby, driving business growth during the forecast period.